In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will acquire treatment right up until disorder progression or perhaps the members are not able to tolerate the study drugs. Possible new ways with the analysis and treatment of AML. https://ricardozlwhu.ambien-blog.com/38259907/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know